Clinical Report: Persistent Uterine Inflammatory Myofibroblastic Tumor with IGFBP5-ALK Fusion Exhibiting Continued Response to Iruplinalkib
Overview
This report details a case of recurrent uterine inflammatory myofibroblastic tumor (IMT) with an IGFBP5-ALK fusion that achieved a complete response to the second-generation ALK-TKI, iruplinalkib, after resistance to crizotinib. This finding suggests a potential therapeutic strategy for ALK-rearranged IMTs.
Background
Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal neoplasms that can mimic other uterine tumors, complicating diagnosis. Approximately 50% of IMTs harbor ALK gene rearrangements, making ALK-TKIs a promising treatment option. However, the efficacy of these inhibitors in uterine IMTs has not been well established, highlighting the need for further investigation.
Data Highlights
This case study presents a unique instance of a 58-year-old woman diagnosed with recurrent uterine IMT, initially misclassified as a myxoid leiomyoma and later as leiomyosarcoma. After confirming the presence of the IGFBP5-ALK fusion, the patient was treated with sequential ALK-TKIs, achieving a complete response with iruplinalkib following resistance to crizotinib.
Key Findings
Incorporate references or data supporting the effectiveness of sequential ALK-TKI therapy.
Clinical Implications
Healthcare professionals should consider the possibility of uterine IMT in patients with atypical presentations of uterine tumors. The use of ALK-TKIs, particularly iruplinalkib, may provide a viable treatment option for patients with ALK-rearranged IMTs, especially after resistance to first-generation inhibitors.
Conclusion
This case underscores the importance of accurate diagnosis and the potential for targeted therapies in the management of rare tumors like uterine IMT. Further studies are warranted to validate the efficacy of sequential ALK-TKI therapy in similar cases.
